Gefitinib in EGFR 19del recurrent aggressive fibromatosis

Jingjing Wu¹Yanjing guo^2,3Qianming Bai^3,4Juefeng Wan^3,5,6Qifeng Wang^3,4,7Xinhong He^3,8Xiaowei Zhang^2,3Zhiguo Luo^2,3Xin Liu^2,3*Liju Xing^9*

• ¹Fuzhou First Hospital, Fuzhou, China
• ²Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
• ³Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, Shanghai, China
• ⁴Department of Pathology, Fudan University Shanghai Cancer Center, shanghai, China
• ⁵Department of Radiation Oncology, Shanghai Cancer Center, Fudan University, Shanghai, Shanghai Municipality, China
• ⁶Shanghai Clinical Research Center for Radiation Oncology, shanghai, China
• ⁷Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
• ⁸Department of Radiology, Shanghai Cancer Center, Fudan University, Shanghai, Shanghai Municipality, China
• ⁹Jiangyin Hospital of Traditional Chinese Medicine Affiliated to Nanjing University, Wuxi, Liaoning Province, China

We present the first case of a male patient with an epidermal growth factor receptor (EGFR) 19del mutation who was diagnosed with intra-abdominal aggressive fibromatosis and familial adenomatous polyposis. We assessed the clinical response of the patient to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). A remarkable sustained partial response was achieved with the application of gefitinib after progression on multiple lines of therapy. The main adverse event of gefitinib treatment in this patient was a grade 2 rash. (Funded by the National Natural Science Foundation of China [Grant No. 82003061] and the Shanghai Sailing Program [20YF1408800] to Yanjing Guo, the Natural Science Foundation of Shanghai [Grant No. 24ZR1412800] to Xin Liu)